Overview: Growth Hormone-Releasing Hormone TestIntroduction: The Growth Hormone-Releasing Hormone Test measures growth hormone-releasing hormone (GHRH) to diagnose pituitary disorders, causing growth issues or fatigue. Aligned with 2023 Endocrine Society guidelines, it uses an immunoassay for high sensitivity, aiding in endocrine screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in endocrinology for patients with suspected pituitary dysfunction, such as growth hormone deficiency.
Other Names: GHRH Assay, Pituitary Hormone Test.
FDA Status: Laboratory-developed test (LDT), meeting endocrinology standards for diagnostic accuracy.
Historical Milestone: GHRH testing began in the 1980s with pituitary research. Immunoassays improved in the 1990s, enhancing accuracy for pituitary disorders.
Purpose: Diagnoses pituitary disorders, guides treatment, and monitors GHRH levels in patients with growth issues, fatigue, or developmental delays.
Test Parameters: 1. Growth Hormone Releasing Hormone
Pretest Condition: Fasting for 10-12 hours required to stabilize hormone levels. Collect serum or plasma in the morning. Report symptoms like growth issues or fatigue, and list medications.
Specimen: 2-5 mL serum (SST) or 2-4 mL plasma (EDTA). Centrifuge within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document growth issues, fatigue, or history of pituitary disorders. Include current medications, especially growth hormone therapies or steroids.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for pituitary treatment.
Procedural Considerations: Uses an immunoassay to measure GHRH levels. Results are available in 3-5 days, supporting clinical decisions.
Factors Affecting Result Accuracy: Non-fasting, hemolysis, or medications (e.g., corticosteroids) can affect results. Stress or sleep disturbances may alter levels.
Clinical Significance: Abnormal GHRH levels suggest pituitary disorders, prompting further testing or treatment. Normal levels may require additional evaluation.
Specialist Consultation: Consult an endocrinologist for result interpretation and management planning.
Additional Supporting Tests: Growth hormone test, IGF-1, or pituitary MRI to confirm pituitary disorders.
Test Limitations: Non-specific hormone fluctuations may occur. Results require clinical correlation and dynamic testing for accuracy.
References: Endocrine Society Pituitary Guidelines, 2023; Journal of Clinical Endocrinology & Metabolism, Melmed S, 2022.
